HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Democrats, Republicans Agree US FDA’s Food Safety Programs Need Help, Disagree On How

Commissioner Califf Candid About Agency Funding, Abbott Nutrition Plant Problems

Executive Summary

Democrats on Oversight and Investigation Subcommittee support increasing funding for FDA’s regulation of food product manufacturing and marketing, but Republicans advise Commissioner Robert Califf the agency should do more with authority it already has and without adding to its budget.

You may also be interested in...

Rodgers Takes House Energy And Commerce Helm Criticizing ‘Administration Gone Woke’

Day after taking chair of committee with FDA oversight, Rodgers criticizes White House’s declaration extending COVID-19 public health emergency. House Appropriation chair Granger prioritizes cutting spending, boosting military.

‘Change Is Difficult’ But It’s A Must For US FDA's Food Program Culture, Expert Panel Advises

Expert panel notes overlap between cultural and structural changes, advises changes in both areas should be implemented together. Recommendations for culture changes include “commit to an on-going process of culture change from the highest levels of FDA leadership.”

US FDA Needs ‘More Clout’ To Get Supply Chain Information, Califf Says

‘It’s driving me crazy that supply chains are a trade secret,’ FDA commissioner states. Agency also needs more clout to handle accelerated approvals, he tells gathering of industry executives and government policy makers.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts